{"id":"W1592261436","doi":"10.1186/ar1407","title":"An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus","year":2004,"lang":"en","type":"article","venue":"Arthritis Research","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Arthritis Network; School of Medicine, University of California, San Diego; Menzies Institute for Medical Research; National Cancer Institute; Arthritis Society; University of North Carolina at Chapel Hill; Genentech; National Institutes of Health; Biogen; Lupus Research Institute; Pfizer; Natural Sciences and Engineering Research Council of Canada; Dutch Arthritis Association; Oesterreichische Nationalbank; Deutsche Forschungsgemeinschaft; Nuffield Foundation; Physiotherapy Foundation of Canada; Canadian Institutes of Health Research; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Lupus Research Alliance; Wellcome Trust; Newcastle University; National Institute of Allergy and Infectious Diseases; Howard Hughes Medical Institute; Austrian Science Fund; Arthritis Foundation","keywords":"Business","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00223359,0.0002746522,0.001047007,0.0004127423,0.0003689083,0.0001050036,0.0006941363,0.0001192339,0.00002422701],"category_scores_gemma":[0.00006930122,0.0001795224,0.0000721805,0.0006819965,0.0004998298,0.0002495646,0.0001213427,0.0003222282,0.000007401204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007914894,"about_ca_system_score_gemma":0.0003080076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004358178,"about_ca_topic_score_gemma":0.0008600176,"domain_scores_codex":[0.9959423,0.0007672419,0.0007577921,0.0006506954,0.001139711,0.0007422944],"domain_scores_gemma":[0.9975724,0.0006895308,0.0001111686,0.0008870666,0.0004865396,0.0002533543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02203441,0.2499451,0.176533,0.001200965,0.0004641871,0.001580746,0.04620899,0.00008114059,0.321501,0.002596309,0.00007106177,0.1777831],"study_design_scores_gemma":[0.3910865,0.2813497,0.2265592,0.002496805,0.00008497811,0.003011244,0.04200699,0.0009136145,0.0477043,0.0009948435,0.002908095,0.0008837136],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850007,0.007441883,0.000009295466,0.0004667181,0.00005210308,0.006605831,0.0001224165,0.00001475344,0.0002862935],"genre_scores_gemma":[0.9678152,0.03127311,0.0003205763,0.00002634019,0.00009470589,0.0001912149,0.0001041941,0.00004241498,0.0001322224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3690521,"threshold_uncertainty_score":0.732071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09168574659915207,"score_gpt":0.4325235346135642,"score_spread":0.3408377880144122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}